m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01730)
Name
4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid
Synonyms
CHEMBL373275; 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid; BDBM50180608
    Click to Show/Hide
Status
Investigative
Structure
Formula
C20H26O3
InChI
1S/C20H26O3/c1-2-3-4-5-6-7-8-9-10-17-11-13-18(14-12-17)19(21)15-16-20(22)23/h11-14H,2-8,15-16H2,1H3,(H,22,23)
InChIKey
JJPRJMIBECZYNN-UHFFFAOYSA-N
PubChem CID
44406790
TTD Drug ID
D05JPV
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-12 (MMP-12)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). [1], [2]
Matrix metalloproteinase-2 (MMP-2)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [4], [5]
References
Ref 1 The aberrant cross-talk of epithelium-macrophages via METTL3-regulated extracellular vesicle miR-93 in smoking-induced emphysema. Cell Biol Toxicol. 2022 Feb;38(1):167-183. doi: 10.1007/s10565-021-09585-1. Epub 2021 Mar 4.
Ref 2 Synthesis of novel ageladine A analogs showing more potent matrix metalloproteinase (MMP)-12 inhibitory activity than the natural product. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5461-3. doi: 10.1016/j.bmcl.2009.07.099. Epub 2009 Jul 23.
Ref 3 CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion. Thorac Cancer. 2019 Jun;10(6):1479-1488. doi: 10.1111/1759-7714.13097. Epub 2019 May 23.
Ref 4 Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem. 2006 Feb 9;49(3):923-31. doi: 10.1021/jm050787+.
Ref 5 RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. Melanoma Res. 2019 Aug;29(4):382-389. doi: 10.1097/CMR.0000000000000580.